Showing 2301-2310 of 5644 results for "".
- Trefoil Therapeutics Announces Positive Phase 2 Study Data Showing Corneal Regeneration and Vision Recovery Following Descemet Stripping Only (DSO) Surgeryhttps://modernod.com/news/trefoil-therapeutics-announces-positive-phase-2-study-data-showing-corneal-regeneration-and-vision-recovery-following-descemet-stripping-only-dso-surgery/2481137/Trefoil Therapeutics announced positive phase 2 results for TTHX1114 in patients with Fuchs Endothelial Corneal Dystrophy (FECD). TTHX1114, a proprietary engineered fibroblast growth factor-1 (FGF1) variant, is delivered as an intracameral injection into the anterior chamber of the eye. Most
- Iridex to Showcase its Non-Incisional Treatments for Glaucoma and Introduce Sweep Management Software at AAO 2022https://modernod.com/news/iridex-to-showcase-its-non-incisional-treatments-for-glaucoma-and-introduce-sweep-management-software-at-aao-2022/2481130/Iridex will showcase non-incisional glaucoma treatments, introduce its Sweep Management Software, and host 8 physician presentations at the 2022 American Academy of Ophthalmology (AAO) annual meeting in Chicago, September 30 – October 3. MicroPulse Transscleral Laser Thera
- Amydis Enrolls First Participants in PROBE, a Phase 1/2a Trial Evaluating a Novel Retinal Tracer in People with Amyotrophic Lateral Sclerosis or Parkinson’s Diseasehttps://modernod.com/news/amydis-announces-enrollment-of-first-participants-in-probe-a-phase-12a-trial-evaluating-a-novel-retinal-tracer-in-people-with-amyotrophic-lateral-sclerosis-or-parkinsons-disease/2481109/Amydis announced dosing of the first patients in the company’s phase 1/2a trial evaluating AMDXP-2011P, a proprietary small molecule retinal imaging agent “retinal tracer” targeting deposits of alpha synuclein (ASYN) and the TAR DNA-binding protein 43 (TDP-43) in patients w
- Eye PCR to Present Poster Presentations on Fixoflex, a New Intraocular Ophthalmic Implant Designed to Hold an IOL Inside Capsular Baghttps://modernod.com/news/eye-pcr-to-present-poster-presentations-on-fixoflex-a-new-intraocular-ophthalmic-implant-designed-to-hold-an-iol-inside-capsular-bag/2481087/At the ESCRS meeting in Milan, Italy, Eye PCR will provide Poster Presentations on Fixoflex, a new intraocular ophthalmic implant designed to hold an IOL minimizing any decentration and tilt inside of the eye’s natural capsular bag. According to Amsterdam-based Eye PCR,
- New MaximEyes.com Software Designed to Simplify EHR Navigation and Patient Flowhttps://modernod.com/news/new-maximeyescom-software-designed-to-simplify-ehr-navigation-and-patient-flow/2481076/First Insight has introduced MaximEyes.com, which is desinged go allow eye care processionals to access data—anywhere, anytime, from any device—in a web browser or via a local server.
- NIH Researchers Develop Gene Therapy for Rare Ciliopathyhttps://modernod.com/news/nih-researchers-develop-gene-therapy-for-rare-ciliopathy/2481074/Researchers from the National Eye Institute (NEI) have developed a gene therapy that rescues cilia defects in retinal cells affected by a type of Leber congenital amaurosis (LCA), a disease that causes blindness in early childhood. Using patient-derived retina organoids (also known as retinas-in-
- Tarsus Submits New Drug Application to the FDA for TP-03 for the Treatment of Demodex Blepharitishttps://modernod.com/news/tarsus-submits-new-drug-application-to-the-fda-for-tp-03-for-the-treatment-of-demodex-blepharitis/2481073/Tarsus Pharmaceuticals announced that it has submitted a new drug application (NDA) to the FDA for TP-03 (lotilaner ophthalmic solution, 0.25%) for the treatment of Demodex blepharitis. Demodex blepharitis is a highly prevalent eyelid m
- Glaukos Announces More Than 1 Million iStent Devices Implanted Worldwidehttps://modernod.com/news/glaukos-announces-more-than-1-million-istent-devices-implanted-worldwide/2481064/Glaukos announced that it has reached a milestone with its iStent family of technologies having now been implanted in more than 1 million procedures worldwide. “One million iStents implanted is a tremendous accomplishment and I’m grate
- Bausch + Lomb and Novaliq Announce FDA Filing Acceptance for Investigational Treatment NOV03 (Perfluorohexyloctane)https://modernod.com/news/bausch-lomb-and-novaliq-announce-fda-filing-acceptance-for-investigational-treatment-nov03-perfluorohexyloctane/2481063/Bausch + Lomb and Novaliq announced that the FDA has accepted the new drug application (NDA) filing for investigational treatment NOV03 (perfluorohexyloctane). A potential first-in-class eye drop with a novel mechanism of action, NOV03 is an investigational therapy to treat the signs an
- eSight and Marathon Medical Partner to Provide Sight Medical Devices to the US Department of Veterans Affairshttps://modernod.com/news/esight-and-marathon-medical-partner-to-provide-sight-medical-devices-to-the-us-department-of-veterans-affairs/2481043/Vision-enhancement platform eSight and Marathon Medical Corp., a SDVOSB (Service-Disabled Veteran Owned Small Business) certified distributor to veteran medical facilities across the United States, announced that the’ve partnered to provide eSight 4 assistive eyewear medical devices to